ASCO Connection

July 2017

Issue link:

Contents of this Issue


Page 53 of 67

O ver the past year, CancerLinQ LLC, a wholly owned nonprofit of ASCO, has announced several new collaborations with a variety of organi- zations in cancer care. This multidisci- plinary coalition of leaders is commit- ted to accelerating the ability to gather new insights from the CancerLinQ ® platform. The expert guidance from these partners from the public, private, and not-for-profit sectors will help to improve quality, efficiency, and value for the entire cancer care continuum. A new collaboration with the U.S. Food and Drug Administration (FDA) will har- ness cancer patient information and big data analytics to examine the real-world use of emerging and newly approved cancer therapies. CancerLinQ and FDA will collaborate to use data from Cancer- LinQ to grow the knowledge base about patterns of care across all cancer types and therapies, accelerate development of novel insights that might otherwise be challenging to obtain through standard research initiatives and data collection means, and inform FDA regulatory strat- egy and decision-making processes. An additional effort will facilitate the exchange of information between CancerLinQ participating oncology practices and the National Cancer Insti- tute's (NCI) Surveillance, Epidemiology, and End Results (SEER) program, the primary source of data on cancer inci- dence and survival in the United States. This collaboration aims to put valuable population-level cancer data at oncolo- gists' fingertips, while also strengthen- ing the nation's cancer surveillance efforts through a national data-sharing collaboration. CancerLinQ has also announced official partnerships with a number of organi- zations, including the American Soci- ety of Radiation Oncology (ASTRO), American Academy of Physician Assis- tants (AAPA), College of American Pathologists (CAP), Cancer Informatics for Cancer Centers (CI4CC), Hematol- ogy/Oncology Pharmacy Association (HOPA), Society of Gynecologic Oncol- ogy (SGO), Oncology Nursing Society (ONS), and National Comprehensive Cancer Network (NCCN). In addition, AstraZeneca is the founding enterprise partner for CancerLinQ Discovery™, which launched in November 2016 and will provide curated, de-identified sets of clinical data for those interested in pursuing hypothesis-driven research. Together, these partnerships will help CancerLinQ achieve its vision of build- ing strategic alliances to create a mul- tidisciplinary coalition that learns from every patient to rapidly improve the quality of care for people with cancer. Leaders from these groups will engage with the CancerLinQ Oncology Leadership Council and other Can- cerLinQ advisory groups. CancerLinQ believes that bringing together the best minds in the cancer community can strengthen the platform's role as a go-to resource for the health care community and improve the lives of patients around the world for genera- tions to come. For more information on the latest collaborations, visit CancerLinQ is a powerful platform containing vast amounts of real-world cancer information. This national ini- tiative will allow cancer providers to improve the quality and value of care by analyzing millions of cancer patient medical records, uncovering patterns and trends, and measuring their care against that of their peers and recom- mended guidelines. CancerLinQ and CancerLinQ Discovery are projects of CancerLinQ LLC. For more information on how to participate or partner with CancerLinQ, please visit • CancerLinQ is supported in part through the Conquer Cancer Founda- tion of ASCO, whose generous donors have helped make the system possible. SUPPORTED 52 I 07.2017 FROM THE SOCIETY l Quality & Guidelines CancerLinQ Unites Oncology Care Leaders to Strengthen Resources and Improve Patient Care

Articles in this issue

Links on this page

Archives of this issue

view archives of ASCO Connection - July 2017